Alivus Life Sciences Ltd
Alivus Life Sciences Ltd Share Price Today: Live Updates & Key Insights
Get insights on Alivus Life Sciences Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Alivus Life Sciences Ltd Share Price Chart
ALIVUS at 10 Jul 2026 06:26 PM Pharmaceuticals
1160.10 +17.20(+1.50%)
Lowest Today 1143.60
Highest Today 1164.60
Today's Open 1158.00
Prev. Close 1142.90
52 Week High 1225.10
52 Week Low 819.00
Alivus Life Sciences Ltd Fundamentals
Traded Volume: 73,798
Market Cap(Cr): 14,239
Avg Traded Price 1159.04
1 Year return 15.74%
Upper Circuit 1,164.6
Lower Circuit 1,143.6
P/E TTM 25.00
P/B Ratio 4.210
Traded Value(Cr) 856.13
EPS TTM 45.990
Book value/Share 271.490
Dividend Yield 1Y 0.43%
Alivus Life Sciences Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Alivus Life Sciences Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Alivus Life Sciences Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +0.08%
1M +12.09%
3M +11.28%
1Y +15.74%
YTD +25.93%
Alivus Life Sciences Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Alivus Life Sciences Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 50907.00
Day Before Yesterday 1.62L
1W Avg 73837.20
1M Avg 1.20L
3M Avg 1.09L
Alivus Life Sciences Ltd Technical Details
Alivus Life Sciences Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 1148
Support 2 1135
Support 3 1127
Pivot Point : 1156
Resistance 1 1169
Resistance 2 1177
Resistance 3 1190
Alivus Life Sciences Ltd Corporate Actions
Alivus Life Sciences Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Alivus Life Sciences Ltd’s capital allocation strategies.
All
Ex-Date 01-Sep-2025 Type D Description 5.00/share@250.00% Record Date 01-Sep-2025 Ratio 250.00
Ex-Date 17-Oct-2023 Type D Description 22.50/share@1125.00% Record Date 17-Oct-2023 Ratio 1125.00
Ex-Date 24-Mar-2023 Type D Description 21.00/share@1050.00% Record Date 24-Mar-2023 Ratio 1050.00
Ex-Date 15-Sep-2022 Type D Description 10.50/share@525.00% Record Date - Ratio 525.00
Ex-Date 22-Nov-2021 Type D Description 10.50/share@525.00% Record Date 23-Nov-2021 Ratio 525.00
Dividends
Announcement Date 01-Sep-2025 Ex Dividend Date 01-Sep-2025 Dividend(%) 250
Announcement Date 17-Oct-2023 Ex Dividend Date 17-Oct-2023 Dividend(%) 1125
Announcement Date 24-Mar-2023 Ex Dividend Date 24-Mar-2023 Dividend(%) 1050
Announcement Date 15-Sep-2022 Ex Dividend Date 15-Sep-2022 Dividend(%) 525
Announcement Date 22-Nov-2021 Ex Dividend Date 22-Nov-2021 Dividend(%) 525
Bonus
No Bonus has been declared by ALIVUS
Splits
No Split has been declared by ALIVUS
Others
Rights No Rights has been declared by ALIVUS
Alivus Life Sciences Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Alivus Life Sciences Ltd with leading peers in the pharmaceuticals & biotechnology sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Alivus Life Sciences Ltd's relative performance and valuation against major competitors.
Stock Name Syngene International Ltd ₹420.35 (+1.19%) M. Cap (Cr) 169.68 1 Yr Return (%) -34.24% P/E (TTM) 53.58 PB Ratio 3.51
Stock Name Alembic Pharmaceuticals Ltd ₹837.40 (+2.51%) M. Cap (Cr) 164.60 1 Yr Return (%) -15.04% P/E (TTM) 24.39 PB Ratio 2.90
Stock Name Jubilant Pharmova Ltd ₹964.20 (-0.52%) M. Cap (Cr) 153.60 1 Yr Return (%) -16.08% P/E (TTM) 38.54 PB Ratio 2.17
Stock Name Alivus Life Sciences Ltd ₹1160.10 (+1.50%) M. Cap (Cr) 142.39 1 Yr Return (%) +15.74% P/E (TTM) 25.22 PB Ratio 4.27
Stock Name Corona Remedies Ltd ₹2042.80 (+0.99%) M. Cap (Cr) 124.94 1 Yr Return (%) NaN% P/E (TTM) 67.49 PB Ratio 16.73
Stock Name Shilpa Medicare Ltd ₹627.15 (+0.78%) M. Cap (Cr) 122.66 1 Yr Return (%) +47.84% P/E (TTM) 50.41 PB Ratio 4.73
Stock Name Marksans Pharma Ltd ₹272.40 (-1.77%) M. Cap (Cr) 123.44 1 Yr Return (%) +5.23% P/E (TTM) 29.54 PB Ratio 4.08
Alivus Life Sciences Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Alivus Life Sciences Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2026 565.41 Mar 2025 391.52 Mar 2024 413.52 Mar 2023 313.40 Mar 2022 597.58
PARTICULARS Investing Activities Mar 2026 -570.15 Mar 2025 -615.64 Mar 2024 -116.48 Mar 2023 -154.14 Mar 2022 -122.23
PARTICULARS Financing Activities Mar 2026 -64.34 Mar 2025 -6.23 Mar 2024 -279.44 Mar 2023 -387.59 Mar 2022 -78.80
PARTICULARS Net Cash Flow Mar 2026 -69.08 Mar 2025 -230.35 Mar 2024 17.59 Mar 2023 -228.33 Mar 2022 396.56
Alivus Life Sciences Ltd Shareholding Pattern
This shows the ownership breakdown of Alivus Life Sciences Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 74.87%
Public 12.55%
Other Institutions 1.64%
FII 5.3%
Mutual Funds 5.63%
About Alivus Life Sciences Ltd
Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune. Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to `Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company. The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business. The first product registered with USFDA in 2003. The Company acquired Glaxo SmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat in 2003. It established manufacturing plant at Kurkumbh, Maharashtra in 2002. In 2004, it commenced manufacturing at Mohol, Maharashtra. In 2013, the Company commenced manufacturing at Dahej, Gujarat. The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019. The Company increased its API manufacturing capabilities by enhancing the existing production capacities at Ankleshwar Dahej facilities in FY 2023, by an aggregate annual total installed capacity of 640 KL.The Company expanded projects with additional 240 KL at Dahej in 2023. The brownfield expansion at Dahej for Oncology Plant was completed. Out of the 2 independent modules, one module commissioned 100%. 192 KL out of the 400 KL intermediate manufacturing block at Ankleshwar commissioned in 2023. The Company came up with an IPO of 21,022,222 Equity Shares comprising a Fresh Issue of 14,722,222 Equity Shares and Offer for Sale of 6,300,000 Equity Shares aggregating to Rs 1513.6 Crores in August, 2021.FY24 ushered in a new chapter with Nirma Limited, a diversified conglomerate with interests in consumer products, cement, chemicals, and pharmaceuticals, acquiring a majority stake in GLS. In FY 2023-24, 75% of the equity stake of the Company was transferred by the promoter, Glenmark Pharmaceuticals Limited (GPL) to Nirma Limited on March 6, 2024. Resulting this, there was a change in ownership status via share purchase agreement, and Nirma became the new promoter of the Company.A separate facility for Ezetimibe was commissioned and became operational at Ankleshwar in FY25. Two independent modules were commissioned in FY 2025 and made operational at Dahej.
Chairman & Independent Directo
HIREN KARSANBHAI PATEL
Registered office Plot No. 170-172 Chandramouli, Industrial Est.Mohol Bazarpeth, Solapur, Maharashtra, 413213
FAX :91-2189-234456/234246
Background
Incorporation Year 2011
Face Value ₹2.00
Market Lot 1
FAQs on Alivus Life Sciences Ltd
How to buy Alivus Life Sciences Ltd shares?
To buy Alivus Life Sciences Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the market cap of Alivus Life Sciences Ltd?
The company has a market capitalization of ₹14,239.
What is the PE & PB ratio of Alivus Life Sciences Ltd?
PE is 25 and PB is 4.210.
What is the Alivus Life Sciences Ltd dividend for 2025–26?
For the 2025–26 financial year, Alivus Life Sciences Ltd declared a final dividend of 0.43% per share.